StockTipsArenaBeta

BUY Zydus Lifesciences Limited — Ajit Mishra, Religare

BUYZydus Lifesciences Limited
Zydus Lifesciences share price target & all analyst calls

byAjit Mishra, ReligareHorizon: Swing (≤2wk)29 Sept 2026via NDTV Profit (Live)

Entry₹1,217.6Inferred
Target₹1,430
Total upside +17.44% (call closed)
Stop loss₹1,100-9.66% risk
At expiry₹1,132.513 Oct 2026, 3:30 pm
Expired-6.99%auction close
Follow Ajit Mishra for new calls(26% target hit, 122 closed calls)Get alertsWatch ZYDUSLIFE for new buy/sell callsGet alertsSee 282 active Swing picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

Frozen at close · 13 Oct 2026
8 supporting2 neutral0 opposing
Supports the BUY call (8)

The US FDA has accepted the review for FYB206, a Keytruda biosimilar developed by Zydus and Formycon.

BSE · Company Update·13 Oct · today

(opens in new tab)

The USFDA has accepted for review the company's biosimilar candidate FYB206, a Keytruda biosimilar developed in partnership with Formycon.

NSE · Press Release·13 Oct · today

(opens in new tab)

Zydus presented Phase 3 trial data showing improved biochemical response for Saroglitazar compared to placebo.

BSE · Company Update·12 Oct · today

(opens in new tab)

Zydus Lifesciences and MSN have partnered to launch the first generic version of Adempas (Riociguat tablets) in the U.S. market.

BSE · Company Update·5 Oct · 1w ago

(opens in new tab)

The USFDA concluded a cGMP inspection at the company's SEZ II manufacturing plant in Ahmedabad with only one observation and no data integrity issues.

BSE · Company Update·28 Sept · 2w ago

(opens in new tab)
Neutral / worth noting (2)

Zydus hits 52-week high, can the optimism continue?

NewsLivemint·29 Sept · 2w ago

(opens in new tab)

Zydus Lifesciences (NSE:ZYDUSLIFE): Why Did It Publish a Lost Share Certificate Notice?

NewsGoogle News·24 Sept · 3w ago

(opens in new tab)
Weighs against the BUY call (0)

Nothing found in this tip’s window yet.

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Zydus Lifesciences

All analyst calls on Zydus Lifesciences

More from Ajit Mishra, Religare

Every call and its outcome